NEW HAVEN, Conn., June 10, 2019 (GLOBE NEWSWIRE) – BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), announced today that it has completed dosing of the first two cohorts of agitated schizophrenia patients in its Phase 2 efficacy trial of BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine (“Dex”). BTI plans to use the results from this study to pursue two planned Phase 3 pivotal trials in agitated schizophrenia and bipolar disorder patients currently expected to begin in 4Q 2019. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology.
2 Likes